Latest news with #KRAS-driven
Yahoo
30-05-2025
- Business
- Yahoo
Silexion Therapeutics announces preclinical results on SIL204
Silexion Therapeutics (SLXN) announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi therapeutic candidate, SIL204, against human pancreatic, colorectal and lung, NSCLC, cancer cell lines. These results significantly expand SIL204's therapeutic potential beyond pancreatic cancer, allowing it to potentially address major KRAS-driven cancers with substantial unmet medical needs. Following the Company's recent announcement of completion of preclinical studies, a comprehensive analysis of the data has revealed that SIL204 effectively inhibited the proliferation and metabolic activity of human cancer cell lines harboring KRAS G12D mutations across multiple cancer types, resulting in the following obvervations: The data reveals SIL204 successfully inhibited the proliferation and metabolic activity of human cancer cell lines harboring a specific KRAS mutation: GP2D, A427 and Panc-1, in a statistically significant manner. The significant inhibition was observed in a dose-dependent manner down to nanomolar concentrations. As observed in the left hand graph below, a dose-dependent reduction in cell viability was noted in GP2D colorectal cancer cells, even in the absence of external additives, due to the lipid end of SIL204. Notably, as can be seen in the right hand graph below, the Company observed an inhibition rate of approximately 90% in the presence of SIL204 in GP2D colorectal cancer cells. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on SLXN: Disclaimer & DisclosureReport an Issue Silexion Therapeutics Receives Nasdaq Delisting Notice Silexion Completes Key Preclinical Studies for SIL204 Silexion Therapeutics completes preclinical studies on SIL204 Silexion Therapeutics' Promising Future: Buy Rating Backed by Expanding Market Potential and Strong Financial Position Silexion Therapeutics Partners with Catalent for SIL204 Development
Yahoo
30-05-2025
- Business
- Yahoo
Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors
Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three major KRAS-driven cancers: pancreatic, colorectal, and lung (NSCLC). In laboratory studies, SIL204 achieved an impressive ~90% inhibition rate in GP2D human colorectal cancer cells, with significant, dose-dependent reductions also observed in pancreatic (Panc-1) and lung (A427) cancer cell lines harboring the KRAS G12D mutation. This marks a major advance, as KRAS mutations are among the most common and challenging targets in oncology, driving roughly 90% of pancreatic, 45% of colorectal, and 35% of non-squamous NSCLC cases. A hand holding cancer cells with a magnifying glass, highlighting the company's target of curing diseases. SIL204's innovative lipid-conjugated delivery system enhances cellular uptake, enabling high efficacy at nanomolar concentrations and potentially overcoming resistance that limits conventional therapies. The company plans further preclinical studies focusing on lung cancer cell lines to expand the evidence base. With a global market opportunity exceeding $30 billion for these cancer types, Silexion Therapeutics Corp (NASDAQ:SLXN)'s RNAi approach could reshape treatment options for patients with hard-to-treat, KRAS-driven tumors. While we acknowledge the potential of SLXN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLXN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
30-05-2025
- Business
- Yahoo
Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors
Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three major KRAS-driven cancers: pancreatic, colorectal, and lung (NSCLC). In laboratory studies, SIL204 achieved an impressive ~90% inhibition rate in GP2D human colorectal cancer cells, with significant, dose-dependent reductions also observed in pancreatic (Panc-1) and lung (A427) cancer cell lines harboring the KRAS G12D mutation. This marks a major advance, as KRAS mutations are among the most common and challenging targets in oncology, driving roughly 90% of pancreatic, 45% of colorectal, and 35% of non-squamous NSCLC cases. A hand holding cancer cells with a magnifying glass, highlighting the company's target of curing diseases. SIL204's innovative lipid-conjugated delivery system enhances cellular uptake, enabling high efficacy at nanomolar concentrations and potentially overcoming resistance that limits conventional therapies. The company plans further preclinical studies focusing on lung cancer cell lines to expand the evidence base. With a global market opportunity exceeding $30 billion for these cancer types, Silexion Therapeutics Corp (NASDAQ:SLXN)'s RNAi approach could reshape treatment options for patients with hard-to-treat, KRAS-driven tumors. While we acknowledge the potential of SLXN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLXN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
22-05-2025
- Business
- Yahoo
PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment
New Report Covers Silexion Therapeutics, A Unique Precision Oncology Player New York, May 22, 2025 (GLOBE NEWSWIRE) -- PESG Research today announced the release of a report examining Silexion Therapeutics, an innovative biotechnology company developing unique RNA interference (RNAi) therapies targeting KRAS-driven cancers. The below report explores the company's disruptive technological approach, recent scientific milestones, and potential implications for cancer treatment strategies, in the fast growing precision oncology market. Executive Summary The precision oncology landscape is experiencing a potential breakthrough with Silexion Therapeutics' innovative approach to addressing KRAS-driven cancers. KRAS mutations represent one of the most challenging oncogenic drivers in cancer, historically resistant to traditional therapeutic interventions. Silexion's lead candidate, SIL204, represents a novel approach to cancer treatment, demonstrating promising preclinical results in reducing both primary tumor growth and metastatic spread across multiple cancer types, including pancreatic, colorectal, and lung cancers. The company's approach offers a fundamentally different strategy to cancer treatment, with potential to address some of the most aggressive and hard-to-treat malignancies. By targeting genetic mechanisms of cancer progression, Silexion is positioning itself at the forefront of precision oncology research. This report includes partner content. We advise readers to refer to the disclaimers and disclosures included at the end of this report. Technological Platform Silexion's core technology distinguishes itself by targeting KRAS mutations at the genetic level, a fundamentally different approach from traditional small molecule inhibitors. The RNA interference (RNAi) platform aims to prevent the production of oncogenic proteins, offering a potentially more comprehensive method of disrupting cancer cell proliferation. The SIL204 candidate demonstrates the ability to target multiple KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. This broad targeting is critical given the prevalence of KRAS mutations in various cancer types: approximately 90% in pancreatic cancers, 45% in colorectal cancers, and 35% in non-squamous non-small-cell lung cancers. Preclinical Developments A significant milestone was achieved in March 2025 with the completion of orthotopic pancreatic cancer model studies. These studies utilized clinically relevant models where human tumor cells are implanted directly into the pancreas, providing a more accurate representation of cancer progression than traditional xenograft models. The research demonstrated notable efficacy across multiple cancer cell lines. In orthotopic models, SIL204 showed significant reductions in tumor cell numbers across different pancreatic cancer cell lines, with results varying by specific cell line and mutation profile. This approach offers a more nuanced understanding of potential therapeutic interventions. Strategic Approach Silexion has developed a sophisticated approach to drug delivery, focusing on two primary administration routes: systemic delivery for targeting metastatic progression and intratumoral delivery for primary tumor treatment. The company's collaboration with Catalent aims to optimize formulation development and clinical manufacturing processes, enhancing the potential efficacy of SIL204. The company's strategy extends beyond a single cancer type, with ongoing research exploring potential applications in colorectal and lung cancers. This broad approach reflects a comprehensive understanding of KRAS-driven malignancies and their complex biological mechanisms. The Road Ahead Silexion's development roadmap reportedly includes continued preclinical studies, planned toxicology and pharmacodynamic investigations, potential regulatory submissions, and anticipated initiation of human clinical trials in the first half of 2026. While the approach shows significant promise, it is crucial to recognize the challenges inherent in translating preclinical research into clinical treatments. The scientific community will be watching closely as Silexion continues to advance its innovative approach to cancer therapy. If succesfulm Silexion's contribution to the field of cancer therapeutics and precision oncology could be major. News Highlights from Silexion Therapeutics Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies >> Click here to Subscribe for more updates like this or go to & Disclosure: Nothing in this report constitutes medica, financial or professional advice. This report is published by PESG Research . The operators of PESG Research, a digital promotional content brand which is compensated to provide digestable and favorabel coverage of comapnies. This report contains and is a form of paid promotional content or advertisement for Silexion Therapeutics and was produced as part of the fee's they pay PESG's operators, Arx Advisory. This report has not been reviewed or approved by Silexion Therapeutics prior to publication. The operators of PESG Research received or are expected to receive a monthly recurring fee of five thousand united states dollars via wire transfer from Silexion Therapeutics as part of an ongoing agreement starting September 1, 2024 in return for social media distribution and promotional coverage services, and receive additional compensation for non promotional unrelated data and advisory services on top of that. Please review the full disclaimers and compensation disclosures here for further details: Readers are advised to refer to the official materials of the company aforementioned. The report should not be treated as objective. Contacts PESG Editorial Deskronald@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer
Silexion's new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollars a year GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN) ('Silexion' or the 'Company'), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the completion of a comprehensive preclinical study assessing SIL204's therapeutic potential across multiple cancer types beyond pancreatic cancer. The Company is currently finalizing its analysis of the data and expects to announce comprehensive results within the next few days. The now-completed studies evaluated SIL204, the Company's next-generation RNAi therapeutic candidate, in multiple cancer cell lines harboring KRAS mutations: GP2D (colorectal cancer), A427 (lung cancer), and Panc-1 (pancreatic cancer). These cancer types were strategically selected based on their high prevalence of KRAS mutations and significant unmet medical needs. "Completing this expanded preclinical evaluation represents an important milestone in our SIL204 development program," said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. "While our initial focus has been on pancreatic cancer, we recognized the potential of our RNAi approach to address other KRAS-driven malignancies. We look forward to sharing the detailed results from these studies in the coming days after completing the final analysis of the studies data. If positive, we believe these results have the potential to significantly expand our development strategy going forward." KRAS mutations are among the most common oncogenic drivers in human cancers, occurring in roughly 90% of pancreatic cancers, about 45% of colorectal cancers, and around 35% of non-squamous non-small-cell lung cancers. Together, these three indications underpin global treatment markets already worth well over US $30 billion a year1, yet most KRAS variants remain difficult to drug with small-molecule or antibody approaches—underscoring the potential significance of Silexion's RNAi-based strategy. About Silexion TherapeuticsSilexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The Company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: Notice Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion's business strategy, ongoing preclinical studies evaluating SIL204 in colorectal and lung cancer applications, potential expansion of development strategy, plans to announce comprehensive results in the coming days, and the therapeutic potential of SIL204 across multiple cancer types, are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them, or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied by those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion's ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the Company, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. Company ContactSilexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFOmirit@ Markets & IR ContactArx Capital MarketsNorth American Equities Desksilexion@ 1 (i) Pancratic Cancer Treatment Mark; (ii) Colorectal Cancer Therapeutics Market; (iii) NSCLC Lunc Cancer Therapeutics MarketError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
